Ranbaxy Laboratories is trading higher by 1.5% to Rs 423, extending its over 9% rally in past six trading sessions, in an otherwise weak market on the Bombay Stock Exchange (BSE).
The stock has outperformed the market by surging 11% in past seven trading sessions after the pharmaceutical company as entered into an in-licensing agreement with Alembic Pharmaceuticals to exclusively market the generic version of Pfizer Inc’s anti-depression drug Pristiq in the US. The BSE benchmark Sensex and the pharma sector have gain 3% each during the same period.
Meanwhile, an analyst at Edelweiss Securities has upgraded the stock to “buy” with target price of Rs 490 per share.
“The management expects growth momentum to continue led by higher contribution from US on back of launches such as Absorica, Desvenlafaxine and Lipitor,” analyst said in a recent report.
Nomura has also upgraded the stock to "buy" from "neutral" and raised its target price to Rs 475 rupees from Rs 415.
"The organisational restructuring has brought greater clarity and there is strong commitment towards improvement in margins, in our assessment," Nomura said in a note, the Reuters report suggests.
The stock has outperformed the market by surging 11% in past seven trading sessions after the pharmaceutical company as entered into an in-licensing agreement with Alembic Pharmaceuticals to exclusively market the generic version of Pfizer Inc’s anti-depression drug Pristiq in the US. The BSE benchmark Sensex and the pharma sector have gain 3% each during the same period.
Meanwhile, an analyst at Edelweiss Securities has upgraded the stock to “buy” with target price of Rs 490 per share.
“The management expects growth momentum to continue led by higher contribution from US on back of launches such as Absorica, Desvenlafaxine and Lipitor,” analyst said in a recent report.
Nomura has also upgraded the stock to "buy" from "neutral" and raised its target price to Rs 475 rupees from Rs 415.
"The organisational restructuring has brought greater clarity and there is strong commitment towards improvement in margins, in our assessment," Nomura said in a note, the Reuters report suggests.